In GTN, studies have focused on the use of agents that block PD-1 (such as pembrolizumab, toripalimab, camrelizumab), or PD-L1 which is normally expressed by tumor cells and immune cells (such as avelumab) [73]. This evidence concerns the gene CD274 and neoplasm.